bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Growth in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 239,800 shares, a growth of 107.6% from the February 28th total of 115,500 shares. Based on an average daily volume of 261,100 shares, the short-interest ratio is currently 0.9 days. Approximately 2.6% of the company’s shares are short sold.

bioAffinity Technologies Price Performance

Shares of NASDAQ:BIAF opened at $0.27 on Friday. The company has a market cap of $4.22 million, a P/E ratio of -0.33 and a beta of 3.12. The company’s fifty day moving average is $0.58 and its two-hundred day moving average is $1.09. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a 12-month low of $0.25 and a 12-month high of $3.16.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC grew its holdings in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,304 shares of the company’s stock after purchasing an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned about 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.